Roivant Sciences Ltd. appointed Amy Mahery as Chief Commercial Officer. Amy has more than twenty years of industry experience and has been involved in the commercialization and launch of therapies across oncology, neurology and immunology. Most recently, she was the Senior Vice President and Head of the Global Business Franchise, Neurology and Immunology (N&I) at EMD Serono, where she led commercial strategy for the N&I portfolio from clinical development to launch and late lifecycle.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.88 USD | -0.18% | +5.02% | -3.12% |
Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.12% | 8.77B | |
+25.73% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.02% | 233B | |
+5.40% | 201B | |
-9.94% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Roivant Sciences Ltd. Appoints Amy Mahery as Chief Commercial Officer